383 S. Colorow Drive
Salt Lake City
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today. Come join us in our mission to decode biology to radically improve lives, while doing the most impactful work of your life.
Working @ Recursion
61 articles with Recursion
Recursion Releases Open-Source Data from Largest Ever Dataset of Biological Images, Inviting Data Science Community to Develop New and Improved Machine Learning Algorithms for the Life Sciences Industry
Clinical-stage biotech offering unique access to cell biology images with the goal of driving more effective artificial intelligence methods in drug discovery and development
Life science and technology startups led by members of underrepresented communities will be encouraged to apply
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
Recursion Announces Options Exercise by Takeda and Extension of AI-enabled Drug Discovery Collaboration
From collaboration to licensing options in less than 18 months
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016.
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been awarded a 2018 Top Workplaces award by The Salt Lake Tribune.
Recursion announced the company has appointed Tina M. Larson as Chief Operating Officer.
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Recursion announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1 clinical trial of REC-994 in the treatment of cerebral cavernous malformation (CCM).
Medicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals
Recursion Pharmaceuticals, today announced that it has hired Phil Carpino, Ph.D. and Mike Genin, Ph.D., to direct chemistry efforts.
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Recursion Pharmaceuticals is a biotechnology company that combines artificial intelligence, experimental biology, and automation to discover drugs at scale
Recursion Pharmaceuticals Raises Additional Funding, Bringing Total Series A To $15.05 Million For Drug Discovery
Recursion Pharmaceuticals Selects Anaconda To Create Innovative Next Generation Drug Discovery Assay Platform To Eradicate Rare Genetic Diseases